Blood transfusion

FDA Expands Lilly's ALIMTA® (pemetrexed) Label with Combination of KEYTRUDA® (pembrolizumab) and Platinum Chemotherapy for the First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer

Retrieved on: 
Thursday, January 31, 2019
Branches of biology, Blood, Anatomy, Transfusion medicine, RTT, Antifolates, Eli Lilly and Company, Pemetrexed, Platelet, Blood transfusion, Folate, Neutropenia

The most common adverse reactions resulting in discontinuation of ALIMTA in this arm were acute kidney injury (3%) and pneumonitis (2%).

Key Points: 
  • The most common adverse reactions resulting in discontinuation of ALIMTA in this arm were acute kidney injury (3%) and pneumonitis (2%).
  • ALIMTA can cause severe myelosuppression resulting in a requirement for transfusions and which may lead to neutropenic infection.
  • Prior to treatment with ALIMTA, patients must be instructed to initiate supplementation with oral folic acid.
  • Do not administer ALIMTA until the ANC is at least 1500 cells/mm3 and platelet count is at least 100,000 cells/mm3.

2018 Emerging Immunohematology and NAT Technologies, Country Market Shares, Strategic Profiles of Leading Suppliers

Retrieved on: 
Thursday, December 13, 2018
Medicine, Transfusion medicine, Immunology, Immune system, Glycoproteins, Hematology, Antibody, Autotransplantation, Polyclonal antibodies, Immunoassay, Blood transfusion, Immunohaematology

NEW YORK, Dec. 12, 2018 /PRNewswire/ -- 2018 Emerging Immunohematology and NAT Technologies, Country Market Shares, Strategic Profiles of Leading Suppliers

Key Points: 
  • NEW YORK, Dec. 12, 2018 /PRNewswire/ -- 2018 Emerging Immunohematology and NAT Technologies, Country Market Shares, Strategic Profiles of Leading Suppliers
    This 114-page report provides assessments of such technologies as molecular diagnostics, monoclonal and polyclonal antibodies, immunoassays, microtitration plates, IT, lasers, synthetic red cell substitutes, genetically engineered blood components, blood preservation, autologous blood transfusion/freezing and their potential applications for blood banking.
  • ReportLinker is an award-winning market research solution.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Transfusions with Older Blood Linked to Adverse Events, Death, new study finds

Retrieved on: 
Wednesday, November 28, 2018
Blood, Medicine, Transfusion medicine, Anatomy, Hematology, Blood transfusion, Packed red blood cells, Red blood cell, Major trauma, Leukoreduction, Blood management

Major trauma victims who receive transfusions of packed blood 22 days old or older may face increased risk of death within 24 hours, according to a new study in Annals of Emergency Medicine.

Key Points: 
  • Major trauma victims who receive transfusions of packed blood 22 days old or older may face increased risk of death within 24 hours, according to a new study in Annals of Emergency Medicine.
  • "To avoid adverse events or death, patients who require massive transfusions may benefit from receiving fresh stored packed red blood cells, or those stored for 14 days or less."
  • Packed red blood cells aged 22 days or more were associated with a 5 percent increase in mortality risk, according to the study, " Older Blood Is Associated With Increased Mortality and Adverse Events in Massively Transfused Trauma Patients ."
  • Major trauma victims can require massive transfusions of blood or blood products in a very short time.

Global Immunohematology and Infectious Disease NAT Screening Market 2018: Strategic Assessments of Current and Emerging Suppliers

Retrieved on: 
Monday, November 26, 2018
Medicine, Transfusion medicine, Immunology, Immune system, Glycoproteins, Hematology, Autotransplantation, Antibody, Immunohaematology, Blood transfusion, Blood bank, Polyclonal antibodies

The "2018 Global Immunohematology and Infectious Disease NAT Screening: Market Shares by Country, Emerging Technologies, Strategic Profiles of Leading Suppliers" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2018 Global Immunohematology and Infectious Disease NAT Screening: Market Shares by Country, Emerging Technologies, Strategic Profiles of Leading Suppliers" report has been added to ResearchAndMarkets.com's offering.
  • This report provides assessments of such technologies as molecular diagnostics, monoclonal and polyclonal antibodies, immunoassays, microtitration plates, IT, lasers, synthetic red cell substitutes, genetically engineered blood components, blood preservation, autologous blood transfusion/freezing and their potential applications for blood banking.
  • The report also presents strategic assessments of current and emerging suppliers of blood banking products, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies.

Janssen Shows Commitment to Advancing the Science and Treatment of Blood Cancers and Related Conditions With More Than 80 ASH 2018 Data Presentations From Differentiated Oncology and Cardiovascular Portfolios

Retrieved on: 
Thursday, November 1, 2018
Medicine, Transfusion medicine, Health, RTT, Tyrosine kinase inhibitors, Breakthrough therapy, Ibrutinib, Piperidines, Blood transfusion, Adverse effect, Heart arrhythmia, Blood bank

Manage cardiac arrhythmias appropriately, and if it persists, consider the risks and benefits of IMBRUVICA treatment and follow dose modification guidelines.

Key Points: 
  • Manage cardiac arrhythmias appropriately, and if it persists, consider the risks and benefits of IMBRUVICA treatment and follow dose modification guidelines.
  • Approximately 6% (CLL/SLL), 14% (MCL), 14% (WM) and 10% (MZL) of patients had a dose reduction due to adverse reactions.
  • Approximately 4%-10% (CLL/SLL), 9% (MCL), and 7% (WM [5%] and MZL [13%]) of patients discontinued due to adverse reactions.
  • Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX.

Following Las Vegas Mass Shooting, High Blood Transfusion Needs Were Met by Existing Supply at Local Hospitals and Blood Suppliers

Retrieved on: 
Monday, October 29, 2018
Blood, Transfusion medicine, Anatomy, Hematology, Medicine, Blood transfusion, United Blood Services, American Red Cross

More than 500 blood components were transfused in the first 24 hours following the incident in Las Vegas.

Key Points: 
  • More than 500 blood components were transfused in the first 24 hours following the incident in Las Vegas.
  • "By analyzing this data and the data from other incidents, we can better predict what blood component needs may be following a mass casualty event to help hospitals, blood suppliers and emergency responders prepare."
  • "Even with the high volume of blood transfusions, in-hospital supplies and rapid supplementation from local blood suppliers met patient need in Las Vegas," said Dr. Ramsey.
  • "More than 700 blood components were rapidly shipped by United Blood Services and the American Red Cross to replenish blood supply at Las Vegas hospitals."

The global blood bank market was valued at $11,527 million in 2017, and is projected to reach $18,649 million by 2025, registering a CAGR of 6.1% from 2018 to 2025

Retrieved on: 
Friday, October 19, 2018
Blood, Anatomy, Transfusion medicine, Blood products, Hematology, Science, Blood bank, Platelet, Whole blood, Red blood cell, Blood transfusion, Blood donation

A blood bank can be a separate free-standing organization or operates as a part of a hospital.

Key Points: 
  • A blood bank can be a separate free-standing organization or operates as a part of a hospital.
  • The global blood bank market is segmented based on product type, function, bank type, end user, and region.
  • Based on product type, the market is classified as whole blood, red blood cell, platelets, plasma, and white blood cell.
  • A comprehensive analysis of the factors that drive and restrain the growth of the global blood bank market is provided.

FDA approves new DNA-based test to determine blood compatibility

Retrieved on: 
Thursday, October 11, 2018
Blood, Transfusion medicine, Medicine, Hematology, Anatomy, Blood transfusion, ABO blood group system, Assay, Blood type, Cross-matching

SILVER SPRING, Md., Oct. 11, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration today approved ID CORE XT, a molecular-based assay used in blood transfusion medicine to help determine blood compatibility.

Key Points: 
  • SILVER SPRING, Md., Oct. 11, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration today approved ID CORE XT, a molecular-based assay used in blood transfusion medicine to help determine blood compatibility.
  • The assay can be used to determine blood donor and patient non-ABO red blood cell (RBC) types.
  • "The approval of the ID CORE XT Test can streamline blood compatibility testing and provides an additional alternative to testing blood with antisera," said Peter Marks, M.D., Ph.D., M.D., director of the FDA's Center for Biologics Evaluation and Research.
  • Human blood can be classified into different groups based on the antigens on the surfaces of red blood cells.

Nucleic Acid Testing Market: Nucleic Acid Testing Kits Dominate Led by PCR High Costs Remain a Key Factor Hampering Adoption in Long Run: Global Industry Analysis 2012 -2016 and Opportunity Assessment 2017 - 2027

Retrieved on: 
Thursday, September 13, 2018
Biology, Chemistry, Biochemistry, Molecular biology, Biotechnology, Medical diagnosis, Nucleic acid test, Blood transfusion, Polymerase chain reaction, Nucleic acid

Increasing demand for nucleic acid testing form blood transfusion centers and blood banks will substantially secure the entire blood transfusion processes, which is anticipated to bolster the growth of the global nucleic acid testing market over the forecast period.

Key Points: 
  • Increasing demand for nucleic acid testing form blood transfusion centers and blood banks will substantially secure the entire blood transfusion processes, which is anticipated to bolster the growth of the global nucleic acid testing market over the forecast period.
  • The market is lucrative, especially for nucleic acid test kits, which is dominated by high demand for polymerase chain reaction (PCR) in the global market.
  • The nucleic acid testing market still faces some limitations in its global demand surge.
  • A few emerging economies lack sophisticated infrastructure required for advanced technologies like nucleic acid testing.

Patient Temperature Monitoring Market Worth $3.21 Billion by 2023

Retrieved on: 
Thursday, September 13, 2018
Medicine, Health, Anesthesia, Intensive care medicine, Monitoring, Nanomedicine, Blood transfusion, Ambulatory care

The growth of this market is driven by the rising prevalence of infectious diseases, increasing geriatric and pediatric population, increasing number of surgical procedures, growing number of blood transfusion procedures, rising awareness about continuous temperature monitoring, and increasing demand for advanced temperature monitoring devices.

Key Points: 
  • The growth of this market is driven by the rising prevalence of infectious diseases, increasing geriatric and pediatric population, increasing number of surgical procedures, growing number of blood transfusion procedures, rising awareness about continuous temperature monitoring, and increasing demand for advanced temperature monitoring devices.
  • On the basis of products, the Patient Temperature Monitoring Market is classified into wearable continuous monitoring sensors, smart temperature monitoring patches, table-top temperature monitoring devices, handheld temperature monitoring devices, and invasive temperature monitoring devices.
  • The handheld temperature monitoring devices segment is projected to grow at the highest rate during the forecast period.
  • By end user, the Patient Temperature Monitoring Market is segmented into hospitals, nursing facilities, home care, ambulatory care centers, and other end users (old age homes and blood & tissue banks).